The last close places the company's stock about $0.47 off its 52 week high of $0.59 and $0.01 above the 52 week low of $0.11.
For the quarter ended June 30, 2016, ImmunoCellular incurred a net loss of $5.3 million, or $0.06 per basic and diluted share, compared to a net loss of $3.2 million, or $0.03 per basic and diluted share, for the quarter ended June 30, 2015.
ImmunoGen, Inc. (IMGN) recently recorded -3.85 percent change and now at $2.75 is 8.7 percent away from its 52-week low and down -83.42 percent versus its peak.
ImmunoCellular Therapeutics, Ltd.is a clinical-stage biotechnology company. The stock's price to price to book (P/B) ratio for the most recent quarter was disclosed as 4.28 and its price to sales (P/S) ratio for the last one year was 3.07. For the current quarter, the company has high EPS estimates of $-0.03 in contradiction of low EPS estimates of $-0.05. After the session opened at $26.59, the stock's price hit the top of $ 26.98 while it touched a low of $ 26.21.
During the last trading session, the expensive price at which share traded, recorded at $0.1200 and the cheapest price at share trade was noted at $0.1116. The number of shares now owned by investors is 134.96 mln.
United States of America based company, ImmunoCellular Therapeutics, Ltd.'s (IMUC)'s latest closing price distance was -56.66% from the average price of 200 days while it maintained a distance from the 50 Day Moving Average at -36.74% and -11.05% compared with the 20 Day Moving Average. It has been assigned a low target price of $3 and a high target price of $3. (NASDAQ:PTX) closed down -0.03 points or -5.53% at $0.56 with 3.59 mln shares exchanging hands. The stock stands almost $4.13 off versus the 52-week high of $4.73 and $0.21 above the 52-week low of $0.39. now shares have been rated as "Buy" from 4 Analysts. The current price change puts the market capitalization at $47.49 mln. 2 Months Ago, shares have been suggested as "BUY" from "0" brokerage firms and recommended as "Strong Buy" by "2" brokerage firms. ABR value is precisely based on brokerage recommendations, where out of 2 brokerage recommendations 2 rate ImmunoCellular Therapeutics Ltd (NYSEMKT: IMUC) stock a Strong Buy, 0 rate the stocks of the company a Buy, 0 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Underperform rating was given by 0 analysts and Outperform rating was given by 2 analysts. Investors might also notice that three month ago the Buy recommendations (2) outnumbered Sell recommendations (0). The count of Hold ratings in that period was 2.
Over the past five trading sessions shares of Pernix Therapeutics Holdings, Inc. A look on the firm performance, its monthly performance is -39.51% and a quarterly performance of -57.75%.
Insider Activity: Corporate insiders look optimistic about the outlook of the company stock that they seem to accumulate shares while they have -67.3 retreated so far this year. Current price places the company's stock -59.49% away from its 200-day simple moving average, -9.04%, away from the 50-day average and also -20.05% away from 20-day average.